Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Learn more about this revolutionary cancer treatment.
Understand the Basics
Meet the CRI scientists committed to the development of immunotherapy.
Some will say that immunotherapy became a household word in 2015. That’s in large part to the significant number of FDA approvals. Checkpoint blockade—called so because they “release the brakes” on the immune system, allowing it to mount a stronger and more effective attack against cancer—was FDA approved for melanoma, lung cancer, and kidney cancer. A new type of immunotherapy—oncolytic virus therapy—got approval in October to treat melanoma. And there are now more than 20 approved antibody-based drugs, including new immunotherapies for neuroblastoma and multiple myeloma. Let’s take a look!
2015 was a great year for cancer immunotherapy, and we expect it to be the same in 2016 and beyond, with more treatments—therapeutic vaccines, CAR T cell therapy—joining the list. Stay tuned!
CRI Partners with the Lymphoma Research Foundation to Improve Immunotherapy Evaluation Guidelines for Lymphoma
Read Previous Article
Business Insider Credits CRI with Pioneering Field of Cancer Immunotherapy
Read Next Article
National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006
(800) 992-2623(212) 832-9376Staff Directory
Ariella was diagnosed with Hodgkin lymphoma in 2010, but treatment with the immunotherapy drug nivolumab changed everything and has since inspired her to support lifesaving cancer immunotherapy research.
Atezolizumab’s third approval in the last year provides an important treatment option for a neglected population of patients with bladder cancer